You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Drug Price Trends for GATIFLOXACIN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for GATIFLOXACIN

Average Pharmacy Cost for GATIFLOXACIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
GATIFLOXACIN 0.5% EYE DROPS 61314-0672-25 11.12572 ML 2025-01-22
GATIFLOXACIN 0.5% EYE DROPS 61314-0672-25 11.19772 ML 2024-12-18
GATIFLOXACIN 0.5% EYE DROPS 61314-0672-25 11.26417 ML 2024-11-20
GATIFLOXACIN 0.5% EYE DROPS 60758-0615-25 12.01100 ML 2024-10-23
GATIFLOXACIN 0.5% EYE DROPS 61314-0672-25 12.01100 ML 2024-10-23
GATIFLOXACIN 0.5% EYE DROPS 60758-0615-25 11.13619 ML 2024-09-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for GATIFLOXACIN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
GATIFLOXACIN 0.5% SOLN,OPH Prasco, LLC 60758-0615-25 25ML 3.94 0.15760 ML 2021-07-01 - 2026-06-30 Big4
GATIFLOXACIN 0.5% SOLN,OPH Prasco, LLC 60758-0615-25 25ML 60.82 2.43280 ML 2021-07-01 - 2026-06-30 FSS
GATIFLOXACIN 0.5% SOLN,OPH Prasco, LLC 60758-0615-25 25ML 4.43 0.17720 ML 2022-01-01 - 2026-06-30 Big4
GATIFLOXACIN 0.5% SOLN,OPH Prasco, LLC 60758-0615-25 25ML 60.82 2.43280 ML 2022-01-01 - 2026-06-30 FSS
GATIFLOXACIN 0.5% SOLN,OPH Prasco, LLC 60758-0615-25 25ML 2.61 0.10440 ML 2023-01-01 - 2026-06-30 Big4
GATIFLOXACIN 0.5% SOLN,OPH Prasco, LLC 60758-0615-25 25ML 60.82 2.43280 ML 2023-01-01 - 2026-06-30 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Gatifloxacin Market Analysis and Price Projections

Market Overview

Gatifloxacin, a fourth-generation fluoroquinolone antibiotic, is widely used in the treatment of various bacterial infections, including conjunctivitis, pneumonia, and urinary tract infections. The global Gatifloxacin market is experiencing significant growth driven by increasing demand for effective antibiotic therapies.

Market Size and Growth

The global Gatifloxacin market was valued at USD 315.49 million in 2023 and is expected to reach USD 331.32 million in 2024. By 2030, the market is projected to grow to USD 440.46 million, with a Compound Annual Growth Rate (CAGR) of 4.88%[1][4][5].

Market Segmentation

By Dosage Form

The market is segmented into various dosage forms, including injectable, ophthalmic solution, and tablets. The ophthalmic solution segment is particularly significant due to the high incidence of eye infections and the need for effective treatments[1][2].

By Therapeutic Area

Gatifloxacin is used in several therapeutic areas, including ophthalmology, respiratory infections, and urinary tract infections. The rising prevalence of these infections is a key driver of market growth[1][4].

By Geographical Regions

The market is divided into regions such as North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Emerging markets in Asia-Pacific and Latin America present significant opportunities for growth due to increasing demand for effective antibiotic therapies[1][2].

Market Dynamics

Drivers

  • Increasing Demand for Antibiotics: The rising incidence of bacterial infections and the growing awareness of antimicrobial resistance are driving the demand for effective antibiotics like Gatifloxacin[1][4].
  • Advancements in Drug Formulation: Improvements in drug formulation technology, such as sustained-release formulations, are enhancing the safety and efficacy profiles of Gatifloxacin[1][4].
  • Urban Pollution and Eye Infections: Escalating urban pollution levels are driving the occurrence of eye infections worldwide, increasing the demand for ophthalmic solutions[1].

Restraints

  • Stringent Regulatory Requirements: Strict regulatory frameworks for antibiotic development pose a significant challenge to market growth[1][4].
  • Antibiotic Resistance: The growing threat of antibiotic resistance and potential side effects, such as tendonitis or peripheral neuropathy, are major restraints[1][4].
  • Adverse Effects: The risk of adverse effects associated with Gatifloxacin limits its market adoption[1].

Opportunities

  • Expansion into Emerging Markets: Potential expansion into emerging markets in Asia-Pacific and Latin America offers significant growth opportunities[1][4].
  • Innovation in Drug Delivery Systems: Developing new delivery mechanisms, such as combination therapies and nanotechnology-enabled drug delivery systems, can enhance market growth[1][4].

Challenges

  • Regulatory and Resistance Trends: Companies must navigate evolving regulatory environments and resistance patterns to capitalize on market opportunities[4].
  • Patient Compliance: Addressing adherence and compliance issues among consumers is crucial for sustained market growth[1].

Competitive Landscape

The Gatifloxacin market is competitive, with several key players including Abbott Laboratories, Adore Pharmaceuticals Pvt. Ltd., Allergan, Inc., Apotex Inc., Bristol-Myers Squibb Company, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Knox Life Sciences, Lupin Pharmaceuticals, Inc., Mylan N.V., Novartis AG, Roche Holding AG, and Sandoz International GmbH[4].

Price Projections and Affordability

Current Pricing

The cost for gatifloxacin ophthalmic 0.5% ophthalmic solution is around $47 for a supply of 2.5 milliliters, depending on the pharmacy and location[5].

Discounts and Assistance Programs

Patients can benefit from various discounts, coupons, copay cards, and patient assistance programs, although specific programs for gatifloxacin ophthalmic may be limited[5].

Innovations and Future Outlook

To address the challenges and capitalize on opportunities, innovations in drug delivery systems and combination therapies are crucial. For instance:

  • Sustained-Release Formulations: Enhancing the safety and efficacy profiles through sustained-release formulations can improve patient compliance and reduce side effects[1][4].
  • Combination Therapies: Research into combination therapies using Gatifloxacin alongside other antimicrobial agents could provide comprehensive solutions to combat resistance[1][4].
  • Collaborative Research: Engaging in collaborative research with institutions focusing on antibiotic resistance can yield promising innovations[1].

Key Takeaways

  • The global Gatifloxacin market is projected to grow from USD 315.49 million in 2023 to USD 440.46 million by 2030 at a CAGR of 4.88%.
  • The market is driven by increasing demand for antibiotics, advancements in drug formulation, and rising urban pollution.
  • Key challenges include stringent regulatory requirements, antibiotic resistance, and adverse effects.
  • Innovations in drug delivery systems and combination therapies are essential for future growth.
  • Emerging markets in Asia-Pacific and Latin America offer significant opportunities.

FAQs

What is the current market size of the Gatifloxacin market?

The global Gatifloxacin market was valued at USD 315.49 million in 2023[1][4].

What is the projected growth rate of the Gatifloxacin market?

The market is expected to grow at a CAGR of 4.88% from 2023 to 2030[1][4].

What are the main therapeutic areas for Gatifloxacin?

Gatifloxacin is used in ophthalmology, respiratory infections, and urinary tract infections[1][4].

What are the major challenges facing the Gatifloxacin market?

The major challenges include stringent regulatory requirements, antibiotic resistance, and potential adverse effects[1][4].

How can companies capitalize on emerging market opportunities?

Companies can capitalize on emerging market opportunities by forming strategic alliances with local pharmaceutical distributors and healthcare providers, and by innovating in drug delivery systems and combination therapies[1][4].

Cited Sources

  1. 360iResearch, Gatifloxacin Market Size & Share 2025-2030, December 2024.
  2. MarketResearchIntellect, Gatifloxacin Market Size And Forecast, December 2024.
  3. QYResearch, Global Gatifloxacin API Market Insights, Forecast to 2030.
  4. GIIResearch, Gatifloxacin Market by Route of Administration, Form, Indication ..., December 2024.
  5. Drugs.com, Gatifloxacin ophthalmic Prices, Coupons, Copay Cards & Patient Assistance.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.